Links and Summaries of 2 Hep C Treatment Articles

[Guest guest]

Ligand Partner GlaxoKline Receives Positive Data from Promacta PIII

ENABLE1 Study in Hepatitis C-Related Thrombocytopenia

From the PharmaLive.com News Archive - Jul. 26, 2011

Ligand Pharmaceuticals announced that its partner GlaxoKline has announced

that it received positive data from ENABLE-1, the first of two Phase III studies

examining Promacta (eltrombopag) in patients with hepatitis C-related

thrombocytopenia, and that full data will be released at an upcoming scientific

conference.

Interim Data from Phase 2 Study of Combination Regimen Including VX-222 and

Incivek

From the PharmaLive.com News Archive - Jul. 26, 2011

Vertex Pharmaceuticals announced interim results from ZENITH, an ongoing Phase 2

study designed to assess the safety, tolerability and efficacy of multiple 12-

and 24-week response-guided treatment regimens with VX-222 (400 mg or 100 mg),

its lead polymerase inhibitor in development, in combination with

Incivek(telaprevir) tablets, pegylated-interferon and ribavirin in people with

genotype 1 chronic hepatitis C who were new to treatment.